<DOC>
	<DOCNO>NCT02873598</DOCNO>
	<brief_summary>This dose escalation trial evaluate safety stereotactic body radiotherapy ( SBRT ) deliver 3 fraction patient locally advanced pancreatic cancer ( LAPC ) receive induction chemotherapy ( FOLFIRINOX gemcitabine nab-paclitaxel ) .</brief_summary>
	<brief_title>A Dose Escalation Trial SBRT After Induction Chemotherapy Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description>This phase I study , expansion cohort , 34 patient identify maximum tolerate dose ( MTD ) 3-fraction regimen stereotactic body radiotherapy ( SBRT ) locally-advanced pancreatic cancer patient develop distant progression follow induction chemotherapy ( FOLFIRINOX gemcitabine nab-paclitaxel ) per standard care . After completion induction chemotherapy , stereotactic body radiotherapy SBRT administer 3 fraction , every day , outpatient basis . Dose escalation start dose level 1 ( 9 Gy x 3 fraction ) increase 1 Gy per fraction dose level , dose level 2 10 Gy x 3 fraction dose level 3 11 Gy x 3 fraction .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Histologically cytopathologically confirm adenocarcinoma pancreas . 2 . Locally advanced , unresectable pancreatic cancer confirm multidisciplinary input hepatobiliary surgeon define CT tumor abutment &gt; 180° ( &gt; 50 % ) circumference superior mesenteric artery ( SMA ) celiac axis , unreconstructable superior mesenteric vein ( SMV ) portal vein ( PV ) involvement . 3 . No evidence distant metastasis either prior induction chemotherapy . 4 . Completion least 3 month , 6 month standard induction chemotherapy LAPC , may include FOLFIRINOX gemcitabine nabpaclitaxel , preferably within 24 week longer 8 week . 5 . Pancreatic tumor size ≤ 5 cm . 6 . Age ≥18 year . 7 . ECOG 01 . 8 . Patients must acceptable organ marrow function define : Leukocytes &gt; 3,000/µL Absolute neutrophil count &gt; 1,500/µL Platelets &gt; 100,000/µL Total bilirubin Within 2 x upper limit normal AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 x institutional upper limit normal Creatinine Within 1.5 x upper limit normal OR Creatinine clearance &gt; 60 mL/min patient creatinine level institutional normal 9 . Ability understand follow breathing instruction involve respiratory gating procedure tolerate compression sufficient reduce fiducial motion &lt; = 5mm . 10 . Ability understand willingness sign write informed consent document . 11 . Residual ongoing ≥ Grade 3 treatmentrelated toxicity previous chemotherapy 1 . Patients prior abdominal radiotherapy . 2 . Patients receive investigational agent . 3 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 4 . Contraindication IV contrast 5 . Patients iodine contrast contraindicate . 6 . Pregnant breastfeed woman exclude . Women childbearing potential unwilling unable use acceptable method birth control avoid pregnancy entire study period 4 week study exclude . This apply woman experience menarche undergone successful surgical sterilization postmenopausal ( define amenorrhea least 12 consecutive month , woman hormone replacement therapy serum FSH level great 35 mIU/mL . A negative urine serum pregnancy test must obtain within 14 day prior start study therapy woman childbearing potential . Male subject must also agree use effective contraception period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Induction Chemotherapy</keyword>
	<keyword>Stereotactic Body Radiotherapy ( SBRT )</keyword>
	<keyword>Dose Escalation</keyword>
	<keyword>Locally Advanced Pancreatic Cancer ( LAPC )</keyword>
	<keyword>Maximum Tolerated Dose ( MTD )</keyword>
</DOC>